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ABSTRACT
Introduction: Chronic spontaneous urticaria
(CSU) is a common and hard to treat
condition associated with a substantial
negative impact on patients’ quality of life
(QoL). Clinical studies have shown that
rupatadine is effective and safe in the
treatment of CSU, but data from routine
clinical care are scarce. Therefore, we assessed
the effectiveness and tolerability of rupatadine
in established dosages on CSU activity and
patients’ QoL in a routine daily practice setting.
Methods: This was an open, prospective,
non-interventional study performed in 146
dermatological practices in Germany. CSU
patients for whom treatment with rupatadine
was indicated were eligible to participate. Key
symptoms of urticaria activity and their impact
on patients’ QoL were assessed at the beginning
and the end of treatment. Adverse events (AEs)
and withdrawals, as well as the dosage regimens
chosen, were documented. Patients and
physicians were requested to rate effectiveness
and tolerability of therapy at the final visit. All
statistical analyses were descriptive.
Results: The majority of the 660 patients
screened to be treated (median age 44 years,
IQR = 31–59 years, n = 654) received
rupatadine 10 mg tablets once (477 patients)
or twice (105 patients) daily for a median time
of 28 days. After treatment, 93.2% of the
patients (606/650) reported a clear overall
improvement of symptoms. Rupatadine
significantly reduced the urticaria activity
score (UAS7) as well as the frequency and
severity of existing angioedema episodes.
Similarly all domains of the urticaria-specific
Electronic supplementary material The online
version of this article (doi:10.1007/s13555-015-0089-y)
contains supplementary material, which is available to
authorized users.
M. Metz  K. Weller  M. Maurer
Department of Dermatology and Allergy,
Allergy-Centre-Charite´, Charite´-University Hospital
Berlin, Berlin, Germany
C. Neumeister  U. Schwantes (&)
Department of Medical Science/Clinical Research,
Dr. R. Pfleger GmbH, Bamberg, Germany
e-mail: ulrich.schwantes@dr-pfleger.de
I. Izquierdo
Department of Clinical Research, Uriach Group,
Barcelona, Spain
Rolf-HassoBo¨deker
Department of Statistics, Institute for Medical
Informatics, University Clinic Giessen, Giessen,
Germany
Dermatol Ther (Heidelb) (2015) 5:217–230
DOI 10.1007/s13555-015-0089-y
QoL questionnaire (CU-Q2oL) were markedly
improved. The majority of physicians and
patients rated rupatadine treatment as
effective and well tolerated. There were 39
(5.9%) early treatment withdrawals, and 21
patients (3.2%) experienced AEs.
Conclusion: Rupatadine when given according
to the routine treating schemes improves
symptoms and CU-Q2oL of CSU patients; the
drug is also safe and well tolerated.
Funding: Dr. R. Pfleger GmbH.
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INTRODUCTION
Chronic spontaneous urticaria (CSU) is one of
the most common and disturbing cutaneous
conditions. CSU is characterized by the daily or
almost daily reoccurrence of pruritic wheals,
angioedema, or both, for more than 6 weeks [1].
In the majority of cases, the underlying cause
remains unidentified [1, 2]. The condition often
lasts for years [1, 2]. Besides being bothersome
and debilitating, CSU has a proven substantial
negative impact on quality of life (QoL) of
affected individuals [2–7]. Treatment, which is
almost always provided on an outpatient basis,
is still a challenge. The first line treatment of
CSU, according to the recommendations
of the current EAACI/GA2LEN/EDF/WAO
urticaria guideline [1], is the continued
use of non-sedating, second-generation
antihistamines (nsAHs). These drugs have been
shown to be efficacious and safe in numerous
clinical trials, but real-life data from the use of
these drugs in routine clinical care are limited.
This is especially true for newer nsAHs such as
rupatadine.
Rupatadine, an N-alkyl pyridine derivative, is
a selective oral histamine H1-receptor inverse
agonist, indicated for symptomatic treatment of
allergic rhinitis and urticaria in adults and
children C2 years [8, 9]. The drug exhibits
strong and balanced antagonist activities
towards both histamine H1- and
platelet-activating factor (PAF) receptors (for
review see: [10–16]). Both histamine and PAF
are held to importantly contribute to the signs
and symptoms of CSU, i.e., itchy wheals and
angioedema [17]. Moreover, rupatadine has a
broad profile of anti-inflammatory effects by
inhibiting both inflammatory cells and a range
of mediators involved in the early- and
late-phase inflammatory responses [10, 18, 19].
After oral administration, rupatadine shows a
fast onset of action, producing rapid
symptomatic relief, and a long-lasting ([24 h)
clinical activity, which allows administration
once a day [12, 20]. Rupatadine has undergone
long-term testing (up to 1 year) in compliance
with ICH and EMA guidelines confirming its
good safety profile [21–23]. At the licensed daily
oral dose of 10 mg, rupatadine has no clinically
relevant effects on the cardiovascular system,
cognitive function or psychomotor function
[10, 14].
The current guideline on the management of
urticaria patients recommends aiming for a
complete symptom relief [1]. However, many
patients fail to get satisfactory relief with the
licensed doses [1, 2]. In this case, the European
guideline advises to progressively increase the
conventional dosages of oral nsAHs up to
fourfold in poorly responding patients [1]. In
fact, higher doses of antihistamines are very
common in general practice and in clinical
studies and do show benefits for individual
patients [1, 2, 21, 24]. However, there is little
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information on the use, the effects and safety of
rupatadine in CSU treatment outside of RCTs
neither for the approved nor for higher than
standard doses. To address this gap of
knowledge, we have assessed treatment
responses to rupatadine administered
according to current routine treatment
schemes in a large and diverse population of
CSU outpatients with a special focus on the
effects of therapy on disease activity and




This multicenter, open, prospective,
non-interventional, observational trial was
conducted by 146 dermatologists in private
practices in Germany from April 1, 2011 until
June 30, 2011 (last day of recruitment). The
rupatadine therapy was prescribed by the
participating physicians in the course of
normal outpatient care, was commercially
available and funded according to local
practice in usual routine care. The study
protocol, therefore, did not contain any
specifications regarding dosing of rupatadine
or duration of treatment. Instead, the advising
dermatologists were asked to follow the
recommendations defined in the licensed
approval from the national regulatory
authorities. The contraindications, special
warnings and precautions for use, interactions,
information on use during pregnancy and
lactation, effects on ability to drive and use
machines, and desirable effects specified in the
Summary of Product Characteristics (SmPC) had
to be observed. Prior to the start of this study, all
participating physicians were instructed in the
conduct and documentation of the trial.
Compliance with Ethics
This non-interventional, observational trial
conformed with § 67(6) of the German Drug
Law. Accordingly, the competent authorities,
National Association of Statutory Health
Insurance Physicians, and the central
association of health insurers were given
notice of the study. Approval of an ethical
committee was not required for such a
non-interventional post-registration trial in
Germany. Nevertheless, the study protocol was
submitted to the independent Freiburger Ethics
Committee, Freiburg, Germany, who gave a
favorable recommendation prior to the start of
the study (February 2011). All procedures were
carried out according to the established
regulations and official recommendations of
the Federal Institute for Drugs and Medical
Devices (BfArM) and the Paul-Ehrlich-Institute
(PEI) relating to the conduct of
non-interventional trials [25]. This study was
performed within the indication approved in
the marketing authorization and under
consideration of the contraindications and
precautions defined there. Informed consent
regarding data protection was obtained from all
patients before being included in the study.
Patients
All outpatients with a confirmed diagnosis of
CSU, for whom treatment with a
second-generation H1-antihistamine was
indicated and a rupatadine preparation
containing 10 mg active agent per tablet (e.g.,
Urtimed 10 mg Tabletten, Dr. R. Pfleger
GmbH, Bamberg, Germany, [8]) was prescribed
by the attending physician, were eligible to
enter the trial. Any current and prior
medications were acceptable for their
inclusion. Participants were free to withdraw
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at will at any time. If they were or decided to
withdraw from the study, the reason for
discontinuation had to be specified.
The sample size of this trial was formed
through the number of patients that were
treated during the predetermined study period
by any of the participating dermatologists.
Assessments and Outcome Measures
There were no defined study-related procedures;
measurements were made by the treating
physicians only as determined in the context
of routine patient care. Thus, effectiveness and
safety of therapy were assessed through
measurements made at usual visits. Trial visits
were defined as initial and final (around
4–10 weeks from baseline) visit. An
observation form (CRF) was used to record the
data gathered from every patient. The CRF at
the initial visit included demography, medical
history, suspected triggers, measures for
confirmation of diagnosis, pre- and
concomitant medications, prescribed dosage
and duration of treatment with rupatadine
tablets, the Urticaria Activity Score (UAS7) and
the angioedema score, each of them generated
over seven consecutive days. The UAS,
recommended by the EAACI/GA2LEN/EDF/
WAO guideline, is a simple scoring system,
which captures number of wheals, and intensity
of pruritus [1, 5]. Daily number of hives ratings
[range: 0 = none; 1 =mild (\20 wheals/24 h);
2 =moderate (20–50 wheals/24 h); 3 = intense
([50 wheals/24 h or large confluent areas of
wheals] and severity of itch [range: 0 = none;
1 =mild (present but not annoying or
troublesome); 2 =moderate (troublesome but
does not interfere with normal daily activity
or sleep); 3 = intense (severe pruritus, which is
sufficiently troublesome to interfere with
normal daily activity or sleep] are summed up
to create a daily UAS score (range: 0–6
points/day), the UAS7, that is, the sum score
of seven consecutive days (maximum score of
42). Another measure of disease activity, the
presence and size of a concurrent angioedema,
was recorded on a scale ranging from 0 = none
to 3 = large, and its localization was
documented (eyes, lips or other; free text
entry). At final examination, the following had
to be documented: actual treatment period and
dosing of rupatadine, onset of efficacy,
intended continuation of medication and
dose, physician’s and patient’s assessment of
treatment effectiveness and tolerability, any
adverse drug effects as well as premature
treatment termination, and again the UAS7
and the angioedema score.
Additionally, at the initial and final visit, the
patients were asked to fill in the German version
of the validated Chronic Urticaria Quality of
Life Questionnaire (CU-Q2oL) [3, 6] to assess the
impact of the disease on their quality of life. The
German CU-Q2oL measures health-related QoL
in 6 domains (functioning, sleep, itching/
embarrassment, mental status, swelling/eating,
and limits looks) and comprises 23 items
evaluating the answers on a five-level Likert
scale.
Data Management and Statistics
Data were entered into a data base (MS ACCESS
2003) via single entry. The validity of data was
checked (a) by plausibility checks within the
data base and (b) by a comparison of all data
with the data in 5% of all CRFs. Data were
analyzed by the statistical program SPSS 10.0
(IBM Corporation, NY, USA) solely in an
exploratory sense. Descriptive statistics were
used to report the results. Analyses of all
variables, including effectiveness and
tolerability outcomes, were performed using
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any participant entered into the study who had
the data relevant to that analysis. Distribution
of each variable is presented by median,
minimum, maximum, and interquartile range
(IQR). As normal distribution of the parameters
of interest could not be assumed, change from
baseline UAS7 score and CU-Q2oL was analyzed
using the Wilcoxon signed rank test. The given
computed p values for the observed or a more
extreme result were p\0.001; the p values are
only a measure of the reproducibility of the
observed results.
RESULTS
Trial Population and Patient Baseline
Characteristics
The data of all 660 participants included in this
study were entered into the safety analysis.
According to the observational plan, one
patient was excluded from the evaluation of
efficacy due to a treatment period of less than
7 days, leaving 659 patients for the efficacy
analysis set.
Out of the 660 patients, 422 (63.9%) were
females and 235 (35.6%) were males, while for 3
subjects (0.5%) respective information was
missing. The median age of the patients was
44 years (range 9–92 years, IQR 31–59 years,
n = 654), and the median body weight 73 kg
(range 44–220 kg, IQR 65–82 kg, n = 657).
In 59.6% (391/656) of the patients, urticaria
symptoms occurred daily (15.9%, 104/656) or
almost daily (43.8%, 287/656), whereas 40.4%
(265/656) showed intermittent urticaria attacks. A
concomitant angioedema was present in 22.1%
(133/601) of patients. The most frequently
suspected triggering factors for urticaria signs
and symptoms were stress (41.5%), food and food
additives (20%), illnesses (15.8%) and medication
(12.9%). Prior to enrolment in the study, 66.7%
(440/658) of the patients had received one or
more medications for their CSU; most
frequently used drugs were cetirizine (37.5%)
and loratadine (22.5%). In 68.9% of the
patients, inefficacy was the reason for
changing the medication to rupatadine, and
tolerability problems accounted for 17.5% of all
changes.
Evaluation of Efficacy
The final visit took place after a median time
period of 35 days (min = 1 day,
max = 139 days; n = 639) following the initial
visit. The median actual treatment period
documented at the final visit was 28 days
(min = 1 day, max = 129 days; n = 638). In 508
patients (79.6%), therapy lasted between 15 and
59 days: in 41.4% (264/638) between 29 and
59 days and in 38.2% (244/638) between 15 and
28 days; 13.6% (87/638) of the patients were
treated between 7 and 14 days, 1.1% (7/638)
between 1 and 6 days, and 5.6% over a period of
C60 days (missing data: 22/660). In all, 77.9%
(477/612) of the patients took rupatadine 10 mg
tablets once daily and 17.2% (105/612) took the
study drug twice daily. A dose of 30 mg/day
received 3.4% (21/612) of the patients, and
1.5% (9/612) reported other dosing (missing
data: 48/660). During treatment, 76% (490/645)
of the patients had maintained the prescribed
dose, whereas 16.7% (108/645) had reduced and
another 7.3% (47/645) had increased their dose;
eight patients dropped out. Regular
administration of the drug was confirmed for
521 patients. Concomitant medication was
negated for 565 patients and confirmed for 80
patients. Respective information was missing
for 15 patients. The most commonly used drugs
were corticosteroids (n = 43, e.g., (methyl)
prednisolone) and other antihistamines
(n = 18, e.g., cetirizine, loratadine; ranitidine,
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cimetidine). For 19 patients concomitant
medications for other conditions were recorded.
After treatment with 10 and 20 mg
rupatadine, respectively, an overall
improvement of symptoms was reported by
606 out of 650 patients (93.2%) and negated
by only 44 (6.8%) patients; for 10 individuals,
including eight drop-outs, no data were
available. The median time to change of
symptoms was specified at 4 days
(min = 1 day, max = 40 days, n = 594).
Evaluating disease activity by use of the
UAS7, rupatadine significantly reduced
number of wheals and pruritus severity from a
median value of 25.0 (min = 2.0, max = 42.0,
IQR 18.0–30.0, n = 632) before treatment to 7.0
(min = 0, max = 42.0, IQR 2.0–14.0, n = 632)
post-treatment (Fig. 1). The change from
baseline in these key symptoms of CSU over
the treatment period is in median 15.5
(min = -23.0, max = 42.0, IQR 9.0–22.0,
n = 622, pWilcoxon signed rank test\0.001).
Under treatment with either 10 or 20 mg
rupatadine per day, improvements in the
frequency and severity/size of an angioedema
were observed. At the final visit, 81 (60.9%) out
of the initial affected patients showed a
complete response (i.e., no angioedema) and
42 patients (31.6%) reported clinically
meaningful improvements in the occurrence
and severity of episodes as documented by the
angioedema score; three patients reported
worsening of the still existing angioedema and
nine patients reported new development of an
angioedema.
Before rupatadine treatment, CSU patients
showed major impairment of overall
disease-related QoL (Fig. 2) as well as in all
domains of QoL including sleep, itching/
embarrassment and mental status as measured
by the Cu-Q2oL (Table 1). Under rupatadine
treatment QoL of CSU patients improved
with reductions in all six domains of the
questionnaire from baseline, even in the items I
(functioning) and VI (limits looks). Regarding the
median change in total Cu-Q2oL score of 23.91
(min =-48.91, max = 88.04, IQR = 13.04–36.96,
n = 551), there was an indication of an important
change (pWilcoxon signed rank test\0.001).
Global Assessment of Effectiveness
and Tolerability
According to the observational study protocol,
the data of 651 patients/physicians were
considered relevant for overall assessment of
treatment effectiveness. Figure 3a depicts the
results of this rating as recorded by the
physicians and patients at the final visit. Most
of the dermatologists (558/643, 86.8%) rated
therapy outcome as complete response (328/643)
or as significantly improved (230/643), compared
with 4.5% (29/643) of the physicians who
assessed symptom severity to be unchanged
(26/643) or worse (3/643). The patient ratings
of the global efficacy of treatment with
rupatadine followed similar trends, with only
1.8% (12/648) of patients rated effectiveness of
therapy to be poor. Similarly, a significantly
greater number of patients (622/648, 96%)
assessed treatment outcome as very good (477/
648) or good (145/648).
Tolerability of rupatadine treatment was
rated as very good or good by 87.8% (572/651)
of the physicians and by 95.7% (620/648) of the
patients (Fig. 3b).
The question relating to therapy
continuation with rupatadine was answered
affirmatively for 367 out of 648 patients
(56.6%) and negated for 276 patients (42.6%)
by the physicians after the observational period.
The standard recommended daily dose of 10 mg
of rupatadine was the most frequently
prescribed dosage (271/367, 73.8%).
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Therapy Withdrawals and Adverse Events
Treatment with rupatadine was prematurely
terminated in 39 out of 660 (5.9%) patients.
Reasons for withdrawal were lack of efficacy (20/
39), AEs (7/39) and ‘‘other’’ (6/39) including 5
cases of nonattendance at the final visit, or not
drug related (4/39); for 2 patients respective
information was missing.
Overall, 21 out of the 660 (3.2%) patients
experienced 27 AEs during rupatadine
treatment. The most frequently reported AEs
with an at least possible causal relationship were
fatigue (n = 11), headache (n = 3) and nausea
(n = 3). Treatment with the study drug was
discontinued in 11 out of the 21 patients with
an AE, and in 10 cases medication was
maintained.
DISCUSSION
To our knowledge this is the first observational,
non-interventional study to demonstrate the
effectiveness and favorable tolerability of oral
rupatadine administered according to the
established dosage recommendations in the
treatment of CSU in routine outpatient care.
As CSU has a detrimental effect on both
objective functioning and subjective well-being
[1, 2, 4–7, 10], evaluation of urticaria activity is
Fig. 1 UAS7 score before and after treatment with
rupatadine (n = 622). The bottom and the top of each
notched box are the ﬁrst and third quartiles, and the line
inside the box is the median. The whiskers represent the
lowest extreme value limit still within 1.5 9 IQR
subtracted from the lower quartile, and the upper extreme
value limit still within 1.5 9 IQR added to the upper
quartile. Stars mark extreme values which are either
1.5 9 IQR or more above the third quartile or
1.5 9 IQR or more below the ﬁrst quartile, but which
are not indicated as outliers. The notch around the median
offers a rough approximation to the 95% conﬁdence
interval of the median. The computed p value for the
observed or a more extreme pre- versus post-treatment
difference is p\0.001 (Wilcoxon signed rank test). IQR
interquartile range
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just as important to be looked at as assessment
of the impact of the disease on patients’ QoL.
Therefore, two validated and disease-specific
tools for patient-reported outcomes assessment
were used in the present study: the UAS7 score
for symptoms and the Cu-Q2oL questionnaire
for urticaria-related QoL impairment. Noting
the changes in frequency and severity of itchy
wheals as well as of angioedema episodes is a
useful way of evaluating clinical efficacy [1].
The relevant differences in CSU activity,
observed in the present trial after a median
treatment period of 28 days and determined
through the use of the UAS7 and the
angioedema score, indicated that an oral dose
of 10 mg rupatadine, administered once or
twice daily, produced obvious improvements
in the clinical status of the affected patients.
These results are in line with the clinical
evaluations, on which approval for the drug was
granted. The efficacy of rupatadine in the
treatment of moderate-to-severe CSU was
evaluated in two randomized, double-blind,
placebo-controlled multicentre studies [26,
27]. Both trials showed that rupatadine 10 mg
and 20 mg per day rapidly and significantly
reduced urticaria symptoms and improved
health-related QoL of these patients. A pooled
responder analysis of both studies highlighted
the greater improvements when using the
higher dosage of 20 mg rupatadine daily [24]:
evaluating disease activity by use of the UAS a
significant reduction of at least 75% in the
10 mg (34.8%) and 20 mg (48%) rupatadine
groups as compared to 13.9% in the placebo
group (p\0.0001) was demonstrated. In the
Fig. 2 CU-Q2oL total score before and after treatment
with rupatadine (n = 521). The unﬁlled circles indicate
outliers which are either 3 9 IQR or more above the third
quartile or 3 9 IQR or more below the ﬁrst quartile. The
computed p value for the observed or a more extreme pre-
and post-treatment difference was p\0.001 (Wilcoxon
signed rank test). CU-Q2oL urticaria-speciﬁc QoL ques-
tionnaire, IQR interquartile range
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present trial, the reduction in the UAS7 score
evaluated for the change of the median values
from baseline over the treatment period
(pWilcoxon signed rank test \0.001) indicated a
relevant therapeutic success. Moreover, the
effects of rupatadine treatment seem at least
similar when comparing its efficacy in clinical
trials and a real-life setting.
The majority of the patients in our study
(77.9%) were using the approved (standard)
dose of the drug (10 mg of rupatadine once
daily) which is defined in the current SmPC [8].
Table 1 Disease-speciﬁc quality of life impairment as assessed by the CU-Q2oL questionnaire before and at the end of
treatment with rupatadine 10 mg tablets, once or twice daily
Item N Minimum Lower quartile Median Upper quartile Maximum
Functioning
Before treatment 597 0.00 29.17 45.83 58.33 100.00
After treatment 597 0.00 0.00 12.50 25.00 100.00
Differencea 597 -54.17 12.50 25.00 41.67 91.67
Sleep
Before treatment 619 0.00 31.25 50.00 68.75 100.00
After treatment 619 0.00 6.25 18.75 37.50 100.00
Differencea 619 -62.50 12.50 25.00 43.75 100.00
Itching/embarrassment
Before treatment 617 0.00 43.75 56.25 68.75 100.00
After treatment 617 0.00 6.25 18.75 31.25 100.00
Differencea 617 -31.25 18.75 37.50 50.00 93.75
Swelling/eating
Before treatment 604 0.00 6.25 18.75 37.50 87.50
After treatment 604 0.00 0.00 6.25 12.50 93.75
Differencea 604 -81.25 0.00 6.25 18.75 87.50
Mental status
Before treatment 628 0.00 25.00 41.67 66.67 100.00
After treatment 628 0.00 0.00 16.67 33.33 100.00
Differencea 628 -50.00 8.33 25.00 41.67 100.00
Limits looks
Before treatment 622 0.00 0.00 25.00 50.00 100.00
After treatment 622 0.00 0.00 0.00 25.00 100.00
Differencea 622 -75.00 0.00 12.50 25.00 100.00
CU-Q2oL urticaria-speciﬁc QoL questionnaire
a Before treatment minus after treatment
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Thus, the observed clinical benefits confirmed
that the approved licensed dosage regimen was
adequate for most patients. However, the
non-predetermined dosing strategy allowed in
the present trial reflects real-life use, and
permitted treatment to be tailored to patients’
individual needs, based on their individual
responses to the drug. About 17.2% of the
patients took the higher dosage of 20 mg
rupatadine per day. During treatment, most
patients (76%) maintained the prescribed dose,
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reduced it. This also demonstrates that a daily
dose of 10 and 20 mg, respectively, of
rupatadine successfully managed the
symptoms of urticaria under everyday practice
conditions.
Based on the favorable effectiveness observed
in the present study, the responder rates to
rupatadine treatment under real-life conditions
might be higher than those expected for nsAHs.
A systematic review of responder rates reported
in RCTs indicated that H1-antihistamines
relieve urticaria symptoms effectively only in
\50% of CSU patients [2].
The clinical benefits observed in our trial
were mirrored by pronounced improvements in
all domains of the CU-Q2oL recorded in the
study population. CSU patients are known to
exhibit severely impaired QoL, and our results
confirm this: disease-specific overall QoL was
markedly reduced as assessed by the CU-Q2oL
questionnaire. Regarding the analysis of the six
different domains of the CU-Q2oL, the changes
in all domains can be regarded as meaningful to
patients and indicate clinically relevant
improvements in QoL. With regard to the
CU-Q2oL total score, the median change was
evaluated as important (pWilxocon signed rank test
\0.001). Thus, rupatadine treatment in the
established schemes is suitable to reduce the
burden of recurrent CSU episodes in those
patients. In previous studies, it was shown that
rupatadine was even more effective than
desloratadine, cetirizine and levocetirizine
with regard to both, benefits in clinical
outcome and patients’ QoL [28–30].
The study drug was safe as demonstrated by a
low frequency of AEs and only few withdrawals.
All observed AEs with an at least causal
relationship were well-known side effects of
oral rupatadine [8]. In general, rupatadine
treatment was well tolerated which is reflected
by the subjective assessments of patients and
physicians. The favorable tolerability of
rupatadine at oral doses of 10 and 20 mg daily
has been evidenced in several clinical studies
(reviewed by [10–16]). The most commonly
reported AEs were somnolence (9.5%),
headache (6.9%) and fatigue (3.2%)
(percentages of AEs according to [8]). The
majority of AEs related to rupatadine were of
mild or moderate severity and their incidence
has been similar to those of active comparators
or placebo. The good tolerability of rupatadine
was confirmed in various long-term safety
studies as well [21–23]. Most importantly,
rupatadine has been shown to have no effects
on CNS activity, on objective psychomotor
tasks or on subjective evaluations [31–34], and
has no cardiotoxic effects [35]. In two clinical
studies, it has been demonstrated that the drug
displays unwanted CNS side activities only at
the highest evaluated dose of 80 mg, while
therapeutically relevant lower doses (20 and
10 mg) were similar to placebo [31, 36].
Limitations of the current trial are dictated by
the nature of an open, non-interventional study
design, which follows national regulations and
recommendations. For example, the
heterogeneity of patients, the variable dosage
regimen and lack of a control group limited
relevance of study results, but in particular the
first two parameters are representative of
outpatient routine care. Thus, on the plus side,
the open observational scenario highly reflects
common use of the study drug in real-life
clinical practice of a well-defined and sizable
patient population treated at multiple sites.
Moreover, the validated instruments, the UAS7
and the CU-Q2oL, used in the current trial cover
relevant aspects of disease activity and health
status; they are specifically standardized for
global comprehensive assessment of CSU and
thus, for monitoring treatment efficacy. In this
sense, observational trials serve to verify the
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magnitude of previously reported clinical
results. However, one interesting question
arising out of the study results remains
unanswered: What was the reason for the
prescription of a higher dosage regimen for
some patients?
CONCLUSION
This non-interventional trial confirmed oral
rupatadine to be an efficacious and safe
therapy option in patients with CSU. During
treatment with this second-generation
H1-antihistamine, symptoms of CSU and
patients’ QoL improved, as measured using
validated and standardized instruments. The
results suggest that the established and
currently recommended treatment regimen is
adequate for most patients.
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